# US 2013/0158083 A1 · Metaxalone cocrystals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158083 A1
- Document ID: US20130158083A1
- Status: Published application
- Kind: A1
- Application number: 13/518,177
- Filed: 2010-12-22
- Published: 2013-06-20
- Earliest claimed: 2009-12-23
- Assignees: Nuformix Limited
- Inventors: Joanne Holland; Christopher Frampton; Alan Chorlton; Daniel Gooding
- Web page: https://patentgrep.com/patent/US20130158083A1

## CPC

- C07D 263/24: with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- C07C 55/10: Succinic acid
- C07C 55/14: Adipic acid
- C07C 57/145: Maleic acid
- C07C 57/15: Fumaric acid
- C07C 65/10: Salicylic acid
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalone adipic acid cocrystal, a 1:0.5 metaxalone fumaric acid cocrystal, a 1:1 metaxalone salicyclic acid cocrystal, a 1:0.5 metaxalone succinic acid cocrystal, and a 1:0.5 metaxalone maleic acid cocrystal. The therapeutic uses of these metaxalone cocrystals are described as well as therapeutic compositions containing them.

## Claims

### Claim 1

A metaxalone cocrystal selected from a 1:1 metaxalone adipic acid cocrystal, a 1:0.5 metaxalone fumaric acid cocrystal, a 1:1 metaxalone salicyclic acid cocrystal, a 1:0.5 metaxalone succinic acid cocrystal, and a 1:0.5 metaxalone maleic acid cocrystal.

### Claim 2 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:1 metaxalone adipic acid cocrystal characterized by a powder X-ray diffraction pattern having at least three peaks selected from 8.5, 15.8, 18.9, 20.2, and 23.6 °2θ±0.2°2θ.

### Claim 3 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:1 metaxalone adipic acid cocrystal characterized by a powder X-ray diffraction pattern having peaks selected from 8.5, 15.8, 18.9, 20.2, and 23.6 °2θ±0.2°2θ, or by a powder X-ray diffraction pattern substantially similar to FIG. 1.

### Claim 4 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:0.5 metaxalone fumaric acid cocrystal characterized by a powder X-ray diffraction pattern having at least three peaks selected from 5.6, 11.0, 13.1, 18.3, 21.6, and 22.7 °2θ±0.2°2θ.

### Claim 5 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:0.5 metaxalone fumaric acid cocrystal characterized by a powder X-ray diffraction pattern having peaks selected from 5.6, 11.0, 13.1, 18.3, 21.6, and 22.7 °2θ±0.2°2θ, or by a powder X-ray diffraction pattern substantially similar to FIG. 5.

### Claim 6 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:1 metaxalone salicylic acid cocrystal characterized by a powder X-ray diffraction pattern having at least three peaks selected from 6.8, 16.1, 17.2, 22.6, and 24.6 °2θ±0.2°2θ.

### Claim 7 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:1 metaxalone salicylic acid cocrystal characterized by a powder X-ray diffraction pattern having peaks selected from 6.8, 16.1, 17.2, 22.6, and 24.6 °2θ±0.2°2θ, or by a powder X-ray diffraction pattern substantially similar to FIG. 12.

### Claim 8 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:0.5 metaxalone succinic acid cocrystal characterized by a powder X-ray diffraction pattern having at least three peaks selected from 6.4, 9.7, 10.2, 12.7, 20.6, and 21.7 °2θ±0.2°2θ.

### Claim 9 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:0.5 metaxalone succinic acid cocrystal characterized by a powder X-ray diffraction pattern having peaks selected from 6.4, 9.7, 10.2, 12.7, 20.6, and 21.7 °2θ±0.2°2θ, or by a powder X-ray diffraction pattern substantially similar to FIG. 19.

### Claim 10 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:0.5 metaxalone maleic acid cocrystal characterized by a powder X-ray diffraction pattern having at least three peaks selected from 6.4, 9.7, 10.3, 12.8, 17.8, and 21.9 °2θ±0.2°2θ.

### Claim 11 (depends on 1)

A metaxalone cocrystal of claim 1, wherein the cocrystal is a 1:0.5 metaxalone maleic acid cocrystal characterized by a powder X-ray diffraction pattern having peaks selected from 6.4, 9.7, 10.3, 12.8, 17.8, and 21.9 °2θ±0.2°2θ, or by a powder X-ray diffraction pattern substantially similar to FIG. 26.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising at least one metaxalone cocrystal of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

A method of treating a musculoskeletal condition comprising the step of administering to a patent in need thereof a therapeutically effective amount of at least one metaxalone cocrystal of claim 1.

### Claim 14 (depends on 12)

A method of treating a musculoskeletal condition comprising the step of administering to a patent in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 12.

### Claim 15 (depends on 3)

A pharmaceutical composition comprising a metaxalone cocrystal of claim 3 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 3)

A method of treating a musculoskeletal condition comprising the step of administering to a patent in need thereof a therapeutically effective amount of a metaxalone cocrystal of claim 3.

### Claim 17 (depends on 5)

A pharmaceutical composition comprising a metaxalone cocrystal of claim 5 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 5)

A method of treating a musculoskeletal condition comprising the step of administering to a patent in need thereof a therapeutically effective amount of a metaxalone cocrystal of claim 5.

### Claim 19 (depends on 7)

A pharmaceutical composition comprising a metaxalone cocrystal of claim 7 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 7)

A method of treating a musculoskeletal condition comprising the step of administering to a patent in need thereof a therapeutically effective amount of a metaxalone cocrystal of claim 7.

### Claim 21 (depends on 9)

A pharmaceutical composition comprising a metaxalone cocrystal of claim 9 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 9)

A method of treating a musculoskeletal condition comprising the step of administering to a patent in need thereof a therapeutically effective amount of a metaxalone cocrystal of claim 9.

### Claim 23 (depends on 11)

A pharmaceutical composition comprising a metaxalone cocrystal of claim 11 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 11)

A method of treating a musculoskeletal condition comprising the step of administering to a patent in need thereof a therapeutically effective amount of a metaxalone cocrystal of claim 11.
